Clinical characteristics and outcomes of primary bone lymphoma in Korea
So-Yeon KIM; Dong-Yeop SHIN; Seung-Sook LEE; Cheolwon SUH; Jae-Yong KWAK; Hoon-Gu KIM; Jae-Hoon LEE; Soon-Il LEE; Ye-Rim LEE; Seung-Hwa KANG; Se-Kwon MUN; Min-Jae LEE; Hyo-Rak LEE; Sung-Hyun YANG; Hye-Jin KANG; So-Yeon KIM; Dong-Yeop SHIN; Seung-Sook LEE; Cheolwon SUH; Jae-Yong KWAK; Hoon-Gu KIM; Jae-Hoon LEE; Soon-Il LEE; Ye-Rim LEE; Seung-Hwa KANG; Se-Kwon MUN; Min-Jae LEE; Hyo-Rak LEE; Sung-Hyun YANG; Hye-Jin KANG.
Korean Journal of Hematology
; : 213-218, 2012.
Artículo
en Inglés
| WPRIM | ID: wpr-720167
BACKGROUND:
This study evaluates the effectiveness of immunochemotherapy and radiation therapy in the treatment of patients with primary bone lymphoma (PBL).METHODS:
We retrospectively reviewed the medical records of 33 patients with PBL who were treated at 6 medical centers in Korea from 1992 to 2010. Clinicopathological features and treatment outcomes were analyzed.RESULTS:
The median age of the patients participating in our study was 40 years. The most common sites of involvement were the pelvis (12.36%) and femur (11.33%). CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like regimens were administered to 20 patients (61%), and R-CHOP (rituximab plus CHOP) was administered to the remaining 13 patients (39%). The overall response rate was 89% (complete response, 76%; partial response, 12%). The overall survival (OS) of patients with solitary bone lesions was longer than that of patients with multiple bone lesions (median OS not reached vs. 166 months, respectively; P=0.089). Addition of rituximab to CHOP did not significantly affect either OS or progression-free survival (P=0.53 and P=0.23, respectively). Combining radiation therapy with chemotherapy also did not improve the OS or progression-free survival of patients with solitary bone lesions.CONCLUSION:
Conventional cytotoxic chemotherapy remains an effective treatment option for patients with PBL. Additional benefits of supplementing chemotherapy with either rituximab or radiation therapy were not observed in this study. Further investigation is needed to characterize the role of immunochemotherapy in treating patients with PBL.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados